Overview

WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This is a WHO-sponsored trial. Combination therapy with streptomycin and rifampicin has been the standard antibiotic treatment for M. ulcerans infection since 2004. In March 2010, a WHO Technical Advisory Group recommended that a trial be carried out to develop a fully oral treatment for the disease. Although the current treatment is effective, injection with streptomycin is a problem. Several small observational studies (published and unpublished) have shown that a fully oral treatment is promising. This WHO sponsored study will be a randomized, controlled open label non-inferiority phase II/III, multi-centre trial (1 centre in Benin and 4 centres in Ghana), with two parallel treatment groups. The ultimate goal is to search for an effective alternative treatment to the current standard WHO-recommended therapy for all forms of Buruli ulcer, which includes injections of streptomycin with inherent logistic, operational and safety disadvantages. Financial and material support: 1. American Leprosy Missions, USA 2. Raoul Follereau Foundation, France 3. MAP International, USA 4. Sanofi, France 5. 7th Framework Programme of the European Union: BuruliVac project (241500) 6. Aranz Medical Limited, New Zealand
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University Medical Center Groningen
Collaborators:
Drugs for Neglected Diseases
Faculté de Médecine P&M Curie, Paris-6 - Site Pitié-Salpêtrière, France
Inserm U892/CNRS 699 & labo bactériologie, Université et CHU d'Angers- IRIS, Angers, France
Inserm U892/CNRS 699 bactériologie, Université CHU;Angers- IRIS France
Institute of Tropical Medicine, Antwerp, Belgium
Komfo Anokye Teaching Hospital
Korle-Bu Teaching Hospital, Accra, Ghana
Kumasi Center for Collaborative Research into Tropical Medicine, Kumasi, Ghana
Kwame Nkrumah University of Science and Technology
Ministry of Health, Benin
National Buruli ulcer Control Programme, Ghana Health Service, Accra, Ghana
Noguchi Memorial Institute of Medical Research, Accra, Ghana
Plastic Surgery and Burns Centre, Korle-Bu Teaching Hospital, Accra, Ghana
Program Nat de Lutte contre la Lèpre et l'UB;Ulcère de Buruli, Cotonou, Benin
School of Med Sciences, Kwame Nkrumah Univ of Sci & Techn, Kumasi, Ghana
University of Ghana
University of Groningen
World Alliance for Wound and Lymphoedema Care, Switzerland
Treatments:
Clarithromycin
Rifampin
Streptomycin